Investigational drug · Phase 2
ZEN003694
Also called: ZEN-3694
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for mCRPC, Metastatic Castration-Resistant Prostate Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: May 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
21
Any phase or sponsor naming "ZEN003694"
First trial start
2019
Nov 12, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ZEN003694", any sponsor or status.
Conditions studied
As listed on its trial records.
- mCRPC
- Metastatic Castration-Resistant Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "ZEN003694" as an intervention, largest first.
- ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate CancerPivotal-lookingRecruiting
Zenith EpigeneticsIndustry
NCT04986423 · 200 participants (planned) · Start Sep 8, 2021 · Primary completion Dec 2026
Drug: ZEN003694; Enzalutamide · For: Metastatic Castration-Resistant Prostate Cancer
Sites: Los Angeles, California; San Francisco, California; Whittier, California · 31 sites in all
Zenith EpigeneticsIndustry
NCT03901469 · 115 participants · Start Jun 26, 2019 · Primary completion Mar 7, 2024
Drug: ZEN003694; Talazoparib · For: Triple Negative Breast Cancer
Sites: Gilbert, Arizona; Atlanta, Georgia; Westwood, Kansas · 19 sites in all
- Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET TrialActive, not recruiting
National Cancer Institute (NCI)NIH
NCT05327010 · 88 participants (planned) · Start Nov 14, 2022 · Primary completion Dec 31, 2026
Drug: BET Bromodomain Inhibitor ZEN-3694; Talazoparib · For: Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm
Sites: Duarte, California; Irvine, California; La Jolla, California · 35 sites in all
Zenith EpigeneticsIndustry
NCT02711956 · 75 participants · Start Dec 2016 · Primary completion Nov 2019
Drug: ZEN003694; Enzalutamide · For: Metastatic Castration-Resistant Prostate Cancer
Sites: Los Angeles, California; San Francisco, California; Detroit, Michigan · 8 sites in all
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid TumorsSuspended
National Cancer Institute (NCI)NIH
NCT04840589 · 66 participants (planned) · Start Feb 2, 2022 · Primary completion Sep 1, 2028
Drug: BET Bromodomain Inhibitor ZEN-3694; Ipilimumab and 1 more · For: Metastatic Malignant Solid Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Platinum-Resistant Ovarian Carcinoma and 1 more
Sites: Bethesda, Maryland; New York, New York; The Bronx, New York · 9 sites in all
National Cancer Institute (NCI)NIH
NCT05950464 · 65 participants (planned) · Start Dec 18, 2023 · Primary completion Jun 30, 2027
Drug: BET Bromodomain Inhibitor ZEN-3694; Tuvusertib · For: Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma and 6 more
Sites: Augusta, Georgia; Chicago, Illinois; Iowa City, Iowa · 14 sites in all
- ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruiting
Rahul AggarwalAcademic, hospital or other
NCT04471974 · 61 participants · Start Jan 26, 2021 · Primary completion May 31, 2028
Drug: BET Bromodomain Inhibitor ZEN-3694; Enzalutamide and 1 more · For: Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Metastatic Prostate Small Cell Carcinoma and 3 more
Sites: San Francisco, California; Evergreen Park, Illinois; Ann Arbor, Michigan
National Cancer Institute (NCI)NIH
NCT05422794 · 57 participants (planned) · Start May 18, 2023 · Primary completion Mar 31, 2027
Drug: BET Bromodomain Inhibitor ZEN-3694; Nab-paclitaxel and 1 more · For: Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Triple-Negative Breast Carcinoma and 2 more
Sites: Boston, Massachusetts; Mineola, New York; New York, New York · 6 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07944105 · 57 participants (planned) · Start May 31, 2027 · Primary completion Dec 31, 2030
Drug: ZEN003694; Radiation Therapy · For: Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma
Sites: Houston, Texas
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
NCT06922318 · 50 participants (planned) · Start Aug 19, 2025 · Primary completion Aug 30, 2031
Drug: ZEN-3694; Testosterone cypionate and 2 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Baltimore, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor-Positive Breast Cancer via Induction of miR-34a-5p.
Liu R, Wang X, Branigan TB, et al. · Clin Cancer Res 2025
- An LC-MS/MS method for determination of the bromodomain inhibitor ZEN-3694 and its metabolite ZEN-3791 in human plasma.
Feng Y, Mahdi H, Piekarz R, et al. · Bioanalysis 2024
- Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer.
Kharenko OA, Patel RG, Calosing C, et al. · Cancer Gene Ther 2022
- A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
Aggarwal RR, Schweizer MT, Nanus DM, et al. · Clin Cancer Res 2020
Also in development for mCRPC
- HC-1119Phase 31 trial
Hinova Pharmaceuticals Inc. · MCRPC
- REGN5678NezastomigPhase 23 trials
Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
- TYK-00540Phase 22 trials
TYK Medicines, Inc · mCRPC, HR-positive, HER2-negative Advanced Breast Cancer
- Ga-68-NGULPhase 21 trial
Cellbion Co., Ltd. · Prostate Cancer, mCRPC
- Lu-177-DGULPhase 21 trial
Cellbion Co., Ltd. · Prostate Cancer, mCRPC
- REGN21353Phase 21 trial
Regeneron · Metastatic Castration-Resistant Prostate Cancer, mCRPC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.